Adrenergic agonists induce heterologous sensitization of adenylate cyclase in NS20Y-D2L cells

FEBS Letters

Volumn 497, Issue 2-3, 2001, Pages 85-89

  Johnston, Christopher A ^a   Cumbay, Medhane G ^a   Vortherms, Timothy A ^a   Watts, Val J ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

D2 dopamine receptor; Epinephrine; Heterologous sensitization; Norepinephrine; NS20Y neuroblastoma; Supersensitization

Indexed keywords

ADENYLATE CYCLASE; ADRENALIN; ADRENERGIC RECEPTOR STIMULATING AGENT; CYCLIC AMP; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2L RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; FORSKOLIN; NORADRENALIN; PERTUSSIS TOXIN; QUINPIROLE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; ENZYME ACTIVITY; LONG TERM CARE; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; SENSITIZATION;

ADENYLATE CYCLASE; ADENYLATE CYCLASE TOXIN; ADRENERGIC AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CYCLIC AMP; DOPAMINE ANTAGONISTS; ENZYME ACTIVATION; EPINEPHRINE; FORSKOLIN; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; MICE; NEUROBLASTOMA; NOREPINEPHRINE; PERTUSSIS TOXIN; RECEPTORS, DOPAMINE D2; TUMOR CELLS, CULTURED; VIRULENCE FACTORS, BORDETELLA;

EID: 0035947324     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-5793(01)02442-5     Document Type: Article

References (25)

1. Richfield E.K., Penney J.B., Young A.B. Neuropharmacology. 30:1989;767-777.
2. Tejanibutt S.M. J. Pharmacol. Exp. Ther. 260:1992;427-436.
3. Gehlert D.R., Schober D.A., Gackenheimer S.L. J. Neurochem. 64:1995;2792-2800.
4. Reith M.A., Li M.-Y., Yan Q.-S. Psychopharmacology. 134:1997;309-317.
5. Onali P., Olianas M.C., Gessa G.L. Mol. Pharmacol. 28:1985;138-145.
6. Lanau F., Zenner M.-T., Civelli O., Hartman D.S. J. Neurochem. 68:1997;804-812.
7. Newman-Tancredi A., Audinot-Bouchez V., Gobert A., Millan M.J. Eur. J. Pharmacol. 319:1997;379-383.
8. Odagaki Y., Dasgupta S., Fuxe K. Eur. J. Pharmacol. 291:1995;245-253.
9. Bates M.D., Senogles S.E., Bunzow J.R., Liggett S.B., Civelli O., Caron M.G. Mol. Pharmacol. 39:1991;55-63.
10. Filtz T.M., Guan W., Artymyshyn R.P., Pacheco M., Ford C., Molinoff P.B. J. Pharmacol. Exp. Ther. 271:1994;1574-1582.
11. Zhang L.-J., Lachowicz J.E., Sibley D.R. Mol. Pharmacol. 45:1994;878-889.
12. Watts V.J., Vu M.N., Wiens B.L., Jovanovic V., Van Tol H.H.M., Neve K.A. Psychopharmacology. 141:1999;83-92.
13. Watts V.J., Neve K.A. Mol. Pharmacol. 50:1996;966-976.
14. Nevo I., Avidor-Reiss T., Levy R., Bayewitch M., Heldman E., Vogel Z. Mol. Pharmacol. 54:1998;419-426.
15. Thomas J.M., Hoffman B.B. Mol. Pharmacol. 49:1996;907-914.
16. Watts V.J., Wiens B.L., Cumbay M.G., Vu M.N., Neve R.L., Neve K.A. J. Neurosci. 18:1998;8692-8699.
17. Kerwin R.W., Beats B.C. Neurosci. Lett. 118:1990;164-168.
18. Chen J., Rasenick M.M. J. Pharmacol. Exp. Ther. 275:1995;509-517.
19. Nestler E.J., Aghajanian G.K. Science. 278:1997;58-62.
20. Nordstedt C., Fredholm B.B. Anal. Biochem. 189:1990;231-234.
21. Barovsky K., Pedone C., Brooker G. Mol. Pharmacol. 25:1984;256-260.
22. Amano T., Richelson E., Nirenberg M. Proc. Natl. Acad. Sci. USA. 69:1972;258-263.
23. Van Tol H.H.M., Bunzow J.R., Guan H.-C., Sunahara R.K., Seeman P., Niznik H.B., Civelli O. Nature. 350:1991;610-614.
24. Yamamoto B.K., Novotney S. J. Neurochem. 71:1998;274-280.
25. Xu F., Gainetdinov R.R., Wetsel W.C., Jones S.R., Bohn L.M., Miller G.W., Wang Y.-M., Caron M.G. Nat. Neurosci. 3:2000;465-471.